Acceleron investors dig their heels in on Merck takeover bid
Activist investors are pushing back against Merck & Co’s recent $11.5 billion deal to acquire Acceleron Pharma, arguing that its $180-per-share offer seriously undervalues the […]
Activist investors are pushing back against Merck & Co’s recent $11.5 billion deal to acquire Acceleron Pharma, arguing that its $180-per-share offer seriously undervalues the […]
BMS Reports EMA’s Validation of MAA for Relatlimab and Nivolumab as 1L Treatment for Unresectable or Metastatic Melanoma Published: Oct 1, 2021 | Tags: BMS, […]
The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular […]
Shots: Merck to acquire Acceleron for $180/share in cash making a total equity value of ~$11.5B representing a premium of 2.6% to the stock’s closing […]
After days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 billion, setting up what could be one […]
US biopharma company Acceleron is the next company heading for a takeover by a big pharma group – according to a Bloomberg report citing people […]
Bristol-Myers Squibb has taken another step towards achieving its blockbuster hopes for beta thalassaemia-associated anaemia therapy Reblozyl, after hitting the target in a phase 2 […]
Pfizer and BioNTech Report Results of BNT162b2 to Prevent COVID-19 Published: Apr 2, 2021 | Tags: Pfizer and BioNTech, Report, Results, BNT162b2, Prevent, COVID-19 Acceleron […]
Shots: The P-II PULSAR trial involves assessing Sotatercept (0.3 mg/kg or 0.3 mg/kg, SC, q3w) vs PBO in 106 patients in a ratio (3:3:4) with […]
RedHill Signs a Manufacturing Agreement with Cosmo for Movantik and RHB-204 Published: Feb 19, 2021 | Tags: RedHill, Signs, Manufacturing, Agreement, Cosmo, Movantik, RHB-204 Astellas and […]
Shots: Fulcrum to receive $10M upfront, reimbursement for R&D costs, research, development and commercial milestone of up to $295M for first product commercialized and additional […]
Copyright © 2024 | WordPress Theme by MH Themes